Alternative Name
BTK, BTK acquired resistance
Methodology
Molecular
Test Description

Concurrent bi-directional sequencing of hotpost regions in the BTK and PLC-gamma-2 genes. Analysis includes the BTK mutation C481S and surrounding regions corresponding to amino acids C464 to M509 and the following PLC-gamma-2 mutations and surrounding regions: R665W (W646 to S679), S707 (A681 to M743), and L845F (I839 to V860).

Clinical Significance

This panel detects mutations in BTK and PLC-gamma-2 which are associated with acquired ibrutinib resistance in certain B-cell neoplasms. This panel is appropriate for patients with B-cell neoplasms who have relapsed and/or show acquired (secondary) resistance after an initial response to BTK (Bruton tyrosine kinase) inhibitors.

Specimen Requirements
  • Peripheral blood: 5 mL in EDTA tube.
  • Bone marrow: 2 mL in EDTA tube.
  • FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Storage and Transportation

Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81233, 81320
Medicare MolDX CPT Code(s)*
81479
Turnaround Time

10 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.